NuBiyota is a microbiome therapeutics company focused on the development of novel microbiota-based drugs to restore crucial gut equilibrium. An imbalance in this crucial ecosystem is associated with infections, chronic disease and even neurological dysfunction. NuBiyota is developing a new class of microbiome therapeutics, with multi-strain microbiota candidates for effective microbiota diversity restoration to suppress flares or promote remission in numerous indications.
Find locations served, office locations
- Business Type:
- Industry Type:
- Market Focus:
- Internationally (various countries)
- Year Founded:
Established in 2013, NuBiyota is a pioneer in next-generation microbiome drug development. NuBiyota holds an exclusive license to the groundbreaking research developed at the University of Guelph, and led by co-founder, Dr. Emma Allen-Vercoe (PhD).
Dr. Allen-Vercoe is a prominent researcher in her field, with 25 years of experience in gut microbiology, the microbiota and its influence on health and disease. Dr. Allen-Vercoe has led multiple studies, published numerous academic papers , and has developed cutting edge innovations in her areas of expertise.
NuBiyota employs a world-class group of scientists and is led by a seasoned management team with extensive management and business development experience in the healthcare industry.
Together this team has developed a novel platform and a pipeline of microbiome therapeutic composition candidates for use in the treatment of medical indications, currently undergoing clinical testing.
NuBiyota has entered a strategic collaboration with the Takeda Pharmaceutical Company for the development of NuBiyota’s Microbial Ecosystem Therapeutic products for gastroenterology (GI) indications.
NuBiyota carries out its research activities in its state-of-the-art labs in Guelph, ON, Canada and has established a GMP manufacturing site in Pearl River, NY, USA.